Inotek Pharmaceuticals Corporation Initiates Phase 2 Study With Trabodenoson In Combination With Latanoprost For Patients With Glaucoma Or Ocular Hypertension
3/10/2014 8:37:15 AM
LEXINGTON, Mass.--(BUSINESS WIRE)--Inotek Pharmaceuticals Inc., a leader in the development of innovative products for the treatment of glaucoma, today announced the initiation of a Phase 2 clinical study of its lead product, trabodenoson, in combination with the most widely-prescribed glaucoma drug, the prostaglandin analog latanoprost (LAT), in patients with elevated intraocular pressure (IOP) that remains uncontrolled despite ongoing treatment with latanoprost.
Help employers find you! Check out all the jobs and post your resume.
comments powered by